Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Gastrointestinal Hormonal Regulation of Obesity
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
Phase 1 N=26 New Approaches to Smoking Cessation in Heavy Drinkers
Nicotine Dependence · Cigarette Smoking · Alcohol Consumption
Primary: Number of Participants With Smoking Abstinence at 6 Months — 6; 3 Participants
Phase 4 N=40 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery
Spine Surgery
Primary: Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade — 3.9; 26.29 Minutes
Phase 2 N=9 A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Primary Focal Segmental Glomerulosclerosis
Primary: Changes in Proteinuria (With Stable Renal Function) — 7.6; 7.27 g/day — p=0.49
N/A N=2,300 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients
Low Back Pain
Primary: Number of Patients Who Reported Transition From Acute to Chronic Low Back Pain (cLBP) — 312; 318 Participants
N/A N=106 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Chronic Hepatitis c
Primary: Liver Fibrosis Stage — 3; 1; 1 Participants
Phase 2 N=662 Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF]) — -16.1; -12.9; -12.6 lesion count — p=0.006
N/A N=14 A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
Lung Cancer
Primary: Primary Outcome Variable: Combined AUC of Selected Symptoms Fatigue, Pain, Disturbed Sleep, Lack of Appetite and Drowsiness — 157.4; 81.1; 255.9; 200.8 Units on a scale…
Phase 1 N=34 A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
Healthy
Primary: Observed Phototoxicity — 0.15; 0.15; 0.00; 0.00 Score on a scale — p=1.0000
N/A N=125 Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus
Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg
N/A N=344 New Haven MOMS Partnership
Depression · Stress
Primary: Total Outpatient Mental Health or Substance Abuse Visits — 1.03; 1.21 visits — p=0.172
Phase 3 N=4,200 Telephone Counseling and the Distribution of Nicotine Patches to Smokers
Smoking Cessation
Primary: Number of Participants With Six-month Continuous Abstinence From Cigarettes — 70; 101; 190 Participants
N/A N=41 Modulating Human Cortical Plasticity With Transcranial Electrical Stimulation
Healthy · Schizophrenia
Primary: Change in Amplitude of N100 Component of the Auditory Evoked Potential — -1.1; -0.35; -0.77; -0.33 microvolts
N/A N=30 Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
Wounds
Primary: Positive Predictive Value (PPV) - Ability of Fluorescence Imaging With the MolecuLight i:X to Predict Presence of Bacterial Loads of 104 CFU/g and Greater — 100…